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ABSTRACT: Inhibition of human carbonic anhydrase IX (hCA IX)
has shown to be therapeutically advantageous for treating many
types of highly aggressive cancers. However, designing selective
inhibitors for hCA IX has been difficult due to its high structural
homology and sequence similarity with off-target hCAs. Recently,
the use of glucosyl sulfamate inhibitors has shown promise as
selective inhibitors for hCA IX. In this study, we present five X-ray
crystal structures, determined to a resolution of 1.7 Å or better, of
both hCA II (a ubiquitous CA) and an engineered hCA IX-mimic in
complex with selected glucosyl sulfamates and structurally rationalize
mechanisms for hCA IX selectivity. Results from this study have
allowed us, for the first time, to empirically “map” key interactions of
the hCA IX active site in order to establish parameters needed to
design novel hCA IX selective inhibitors.
■ INTRODUCTION
Hypoxia in solid tumors is a condition commonly associated
with metastatic transitions in tumor cells.1,2 This hypoxic
phenotype in tumor cells results in an outgrowth of their blood
supply, leading to microenvironmental changes consisting of
low oxygen concentration (typically ≤1% of overall oxygen
content) and a decrease in extracellular pH (∼pH 6.5).1 This
induces the tumor cells to transition their general metabolism
from mitochondrial oxidative phosphorylation to glycolysis
often independent of the amount of available O2, a
phenomenon described as the Warburg effect.3,4 As a result
of this glycolytic shift, there is an upregulation of pH
homeostasis factors in tumor cells to establish a regulated
intracellular/extracellular pH gradient.5,6 One pH regulatory
factor that is ubiquitous to hypoxic tumor cells is human
carbonic anhydrase IX (hCA IX).6,7 hCA IX has shown to be a
critical enzyme for tumor cell survival and proliferation due to
its role in maintaining a close-to physiological intracellular pH
in tumor cells.6,8 As such, inhibition of hCA IX activity in
hypoxic tumor cells has proven to be detrimental to the cells
growth and proliferation.7,9−11
hCA IX is a zinc metalloenzyme that catalyzes the reaction
between carbon dioxide and water to produce bicarbonate and
a proton. hCA IX is a homodimer, type 1 transmembrane
enzyme with an extracellular catalytic domain, considered the
primary “druggable” site.12,13 While the expression of hCA IX is
primarily limited to the stomach and GI tract in healthy tissue,
hCA IX expression has been shown to be highly upregulated in
multiple neoplastic tissue types.6,7 Therefore, hCA IX is used as
a prognostic marker for several cancer types.14−16 Because of
hCA IX’s pivotal role in pH regulation in several tumors, its
limited expression in normal human tissue, and its highly drug-
targetable extracellular catalytic domain, hCA IX has been
defined as an excellent drug target.7,9,17
While clinically used inhibitors of hCA currently exist, these
are isoform nonspecific and may result in the inhibition of
ubiquitously expressed CAs (such as hCA I and II) and could
result in unwanted side effects.18 Therefore, isoform specific
hCA IX inhibitors are required. hCA IX inhibitor development
is complicated by the fact that the 15 CA isoforms share a
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conserved active site architecture with limited sequence
variation between residues.19,20 However, isoform selectivity
among hCA inhibitors has been shown to be feasible by
utilizing structural information on the active sites, and a method
termed the “tail approach,” whereby inhibitors are designed
utilizing a chemical group that coordinates to the active site
zinc (zinc-binding group, ZBG) conjugated to a variable “tail”
region designed to interact with residues toward the surface of
the active site (discussed in detail by Pinard et al.19).
We have previously shown that a series of glucosyl
sulfamates, where the sulfamate acts as a ZBG and the glucose
or acetylglucose group acts as the “tail” (Figure 1), are excellent
hCA IX inhibitors that show capabilities to inhibit the enzyme
better than off-target CA isoforms (hCA I and II) and also
show limited membrane permeability allowing for location
specific targeting of the extracellular hCA IX over other
cytosolic hCAs. In addition, we have previously speculated on
structure−activity (SAR) and structure−property relationships
of these inhibitors with the active site of hCA IX and hCA II to
rationalize their inhibition selectivity profiles.21 In this study, we
continue to study this series of hCA IX inhibitors to, for the
first time, empirically “map” regions of selectivity in the hCA IX
active site to determine key properties an inhibitor must exhibit
in order to be isoform selective. To do this, we have solved five
crystal structures of both wild-type hCA II and an engineered
hCA IX-mimic (a molecule of hCA II with active site
substitutions (hCA II numbering used throughout this
manuscript) A65S, N67Q, E69T, I91L, F131V, K170E, and
L204A to “mimic” hCA IX21) in complex with three inhibitors,
denoted 623, 625, and 626 from the previously published
glycoconjugate sulfamate series (see Moeker et al.21), all to a
resolution of 1.7 Å or better. Results from this study will guide
hCA IX selective inhibitor design and aide in the development
of drugs that target the enzyme to treat several cancers.
■ RESULTS AND DISCUSSION
Compound Design and Synthesis. The glucose-based
sulfamate compounds are nonclassical hCA inhibitors as they
comprise a primary sulfamate and not a primary sulfonamide as
the zinc binding group (ZBG). Our group has had substantial
success in developing hCA IX inhibitors through the
combination of the sulfamate ZBG with a carbohydrate
motif.21 The acetylated glucose moiety is common to
compounds 623, 625, and 626; the glucose moiety is attached
via a sulfonamide functionality to a variable linker region that
terminates with the primary sulfamate ZBG. The linker length,
steric bulk, and stereochemistry differ, with a n-pentyl chain
623, pyrrolidine ring 625, and piperidine ring 626 selected to
probe potential differential hCA active site interactions with
hCA II and IX.
The synthetic approach toward the acetylated carbohydrate-
based sulfamates 623, 625, and 626 has been fully described by
us earlier.21,22 The synthesis proceeds in three steps
commencing from reaction of 2,3,4,6-tetra-O-acetyl-1-S-acetyl-
1-thio-β-D-glucopyranose with the corresponding amino
alcohol, followed by oxidation to the sulfonamide, and last,
sulfamoylation of the terminal alcohol functionality to install
the sulfamate ZBG of 623, 625, and 626 (Supporting
Information Scheme 1).
Selective hCA IX Inhibition. Inhibition data for 623, 625,
and 626, and clinically used hCA inhibitor acetazolamide
(AZM) with hCA IX, I, and II (main off-target reservoirs) and
hCA XII (which has also been linked to cancer progression8,16)
are summarized in Table 1. The selectivity ratios for inhibition
of hCA IX and hCA XII over the ubiquitously expressed hCA I
and hCA II are also presented in Table 1.
We have previously discussed the SARs of each of the
compounds in this study extensively (see Moeker et al.).21 In
brief, all compounds showed weakest inhibition of hCA I
compared to hCA II, hCA IX, and hCA XII, which is a common
observation for reported primary sulfonamide and sulfamate
compounds and is desirable as hCA I is considered a main off-
target hCA.19,21 For hCA II, hCA IX, and hCA XII, the SAR
vary, however, there is still a favorable selectivity ratio for each
compound in terms of hCA IX inhibition. In this case, the
inhibition profile for all compounds appears to depend mostly
on the linker, as it is presumed the acetylation sites are present
in the glucose moieties of each compound making the “tail”
region common for each. Observations of selectivity ratios
indicate the use of a five-membered pyrrolidine ring system
shows the highest selectivity (625, I/IX = 4750, II/IX = 360),
followed by a six-membered piperidine ring system (626, I/IX
= 1200, II/IX = 130), and the least selective being a linear
pentyl linker (623, I/IX = 175, II/IX = 5). A similar trend in
selectivity is seen with each compound’s affinity for hCA XII.
The rationale for utilizing acetylated glucosyl tail moieties
allows for significant contributions to the compound’s steric
bulk as well as hydrogen bonding capacity of the “tail” moiety.
As such, compounds 623, 625, and 626 are shown to be
excellent hCA IX inhibitors, all with Ki values of 2 nM (Table
1). In addition to these attributes, it has been previously
demonstrated that the in vitro metabolic stability, plasma
stability, and plasma protein binding characteristics for the
acetyl groups, when presented on a glucose scaffold, allows
these compounds to exhibit properties of ester prodrugs.23
However, as we will show, there is a significant deacetylation of
each of the compounds by both hCA II and the hCA IX-mimic,
Figure 1. Schematic outlining the rational design of glucosyl sulfamate
inhibitors. The general construct shows the primary sulfamate ZBG is
conjugated to an acetylated glucosyl moiety and sulfonamide bridge by
a variable linker region (highlighted in maroon).
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Table 1. Inhibition and Isozyme Selectivity Ratio Data for Human CA Isozymes I, II, IX, and XII with Compounds 623, 625,
and 626, and Clinically Used Acetazolamide (AZM)
Ki (nM)
a selectivity ratiob
compd hCA I hCA II hCA IX hCA XII I/IX II/IX I/XII II/XII
623 350 10 2 9 175 5 39 1
626 2400 265 2 60 1200 133 40 4
625 9500 725 2 1 4750 363 9500 725
AZM 250 12 25 6 10 0.5 42 2
aErrors in the range of ±5% of the reported value from three determinations. bSelectivity is determined by the ratio of Kis for hCA isozyme relative
to hCA IX and XII.
Table 2. X-ray Crystallography Statistics for Data Processing and Refinement of Ligand Bound CAIX-Mimic and CA II Crystal
Structures
hCA IX-mimic:623 4ZWX hCA IX-mimic:625 4ZWY hCA IX-mimic:626 4ZWZ hCA II:623 4ZX0 hCA II:625 4ZX1
space group P21
cell dimensions (Å; deg) a = 42 ± 0.8, b = 42 ± 0.8, c = 72 ± 0.5; β = 104 ± 0.3
resolution (Å) 19.8−1.70 (1.75−1.70) 19.8−1.61 (1.66−1.61) 19.9−1.55 (1.58−1.55) 32.0−1.50 (1.54−1.50) 20.0−1.60 (1.66−1.60)
total reflections 36753 36949 38399 38025 31556
Rsym
a (%) 5.7 (57.3) 4.3 (64.4) 10.3 (62.9) 4.7 (32.1) 6.3 (41.3)
I/σ(I) 20.5 (1.74) 24.5 (1.56) 9.35 (0.38) 47.2 (5.31) 19.61 (2.91)
completeness (%) 93.3 (93.6) 89.1 (84.9) 98.4 (94.2) 98.2 (99.0) 97.8 (97.1)
Rcryst
b (%) 16.0 (22.4) 16.1 (23.6) 15.7 (27.0) 15.5 (22.6) 15.2 (24.7)
Rfree
c (%) 19.2 (25.8) 21.1 (26.8) 19.5 (31.0) 17.3 (27.2) 17.8 (29.8)
no. of protein atoms 2094 2082 2081 2085 2064
no. of water molecules 199 232 264 285 296
no. of ligand atoms 37 28 28 31 31
Ramachandran stats (%):
favored, allowed,
outliers
96.9, 3.14, 0.0 96.1, 3.53, 0.39 96.9, 3.12, 0.0 96.5, 3.54, 0.0 97.2, 2.77, 0.0
av B factors (Å2): main
chain, side chain,
solvent, ligandd
17.3, 21.3, 26.0, 27.5 18.3, 22.3, 47.5, 30.0 17.5, 21.5, 40.5, 31.7 20.5, 24.7, 42.9, 34.5 14.1, 18.6, 21.1, 28.6
aRsym = (∑|I − ⟨I⟩|/∑ ⟨I⟩) × 100. bRcryst = (∑|Fo − Fc|/∑ |Fo|) × 100. cRfree is calculated in the same way as Rcryst except it is for data omitted from
refinement (5% of reflections for all data sets). dValues in parentheses correspond to the highest resolution shell.
Figure 2. Compound 623 bound in the active site of both hCA II (green) and the hCA IX-mimic (cyan). (A) Overlay of the coordinates of
compound 623 (shown as sticks, rmsd = 1.12 Å) from both hCA II (purple) and the hCA IX-mimic (white) with active site residues and relative
bond distances (Å) labeled. Waters are shown as red spheres. (B) Cross-section of the hCA active site marking distance shells relative to the active
site zinc. The selective pocket is highlighted in green, and overlays of compounds ranging in selectivity are shown as sticks. The least selective
compounds (compounds 623, gray, and AZM,12 pink) and highly selective (compound 5d, labeled as per Moeker et al.,21 PDB ID 4R59, green).
Figure was made using PyMol.38
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suggesting a possible “auto-unmasking” of these inhibitors
during delivery (Supporting Information Figure S1). It should
be noted, however, that this phenomenon has only been
recorded in vitro and it is uncertain how this mechanism would
affect these compounds in vivo.24,25 As such, we will not
emphasize in this study the in vitro mechanism of these
compounds as we are unsure of its impact in vivo.
X-ray Crystallographic Results. X-ray crystallography
(statistics summarized in Table 2) was used to analyze the
mode of binding of compound 623 in complex with hCA II (Ki
= 11 nM) and the hCA IX-mimic (hCA IX Ki = 2 nM) to gain
insight in to the ∼5-fold selectivity (Table 1) of 623 for hCA
IX. Structural analysis of the hCA IX-mimic in complex with
623 (Figure 2A) displays direct binding to the active-site zinc
via the primary sulfamate group. Furthermore, binding of 623
causes an almost complete displacement of the ordered water
network in the active site that has been determined important
for catalysis.26,27 The only water present in the enzymes active
site is observed coordinated between the hydroxyl of the side
chain of Thr200 and the NH of the sulfonamide linker of 623
(Figure 2A). The “tail” region of 623, comprising the
sulfamate-linked acetylated glucose moiety shows limited
interaction with the hCA IX-mimic active site. Other primary
interactions are observed occurring between the sulfonyl linker
and Pro202 (Figure 2A). Comparisons of the binding
modalities of compound 623 as it resides in the active site of
hCA II show the interactions are mostly conserved (Figure 2A),
with possible van der Waals (vdw) interactions only occurring
between C1 of the acyl linker of 623 and Phe131. The
conserved interactions between the hCA IX-mimic and hCA II
correlates to the limited difference in Ki values between the
hCA II and hCA IX (Table 1). In addition, cleavage of acyl
groups (most likely through the weak esterase activity exhibit
by hCA II, Figure S1) are observed, specifically on C2 and C3
of the glucose ring moiety (Supporting Information Figure
S2A).24 It is possible this esterase activity is more prevalent in
hCA II, and the deacetylation of the glucose ring in compound
623 may contribute to the slight reduction in Ki value between
hCA II and hCA IX, as glucose groups appear to bind
unfavorably to the active site of hCA II.21,28 It is also observed
that compound 623 shows limited interaction in what has been
defined as the selective pocket of the CA active site, or the region
of the active site farthest from the catalytic zinc that contains
residues that vary between isoforms (reviewed in detail by
Pinard et al.19 and Aggarwal, et. Al.20). The linear pentyl linker
region of compound 623 causes the acetylated glucose group to
extend ∼15 Å from the catalytic zinc, which induces an
extension of this group out of the active site (Figure 2B). This
essentially abolishes any interactions the “tail” region of
compound 623 could form in the enzymes selective pocket. As
such, the importance of this region in the CA active site is
shown in Figure 2B, where the least selective compounds (in
this case acetazolamide and compound 623) form few or no
interactions with residues in the selective pocket which is located
between 10 and 15 Å away from the catalytic zinc. Alternatively,
compounds that show high selectivity for hCA IX (such as
compound 626′ from Moeker et al.,21 Supporting Information
Figure S1) have “tail” groups that interact directly in this region
(Figure 2B).
X-ray crystal structures of compound 625 in complex with
both hCA II and the hCA IX-mimic were determined (statistics
summarized in Table 2). Compound 625 shows a higher
selectivity (∼400-fold) for hCA IX over hCA II with Ki values
of 2 and 740 nM, respectively (Table 1). Similar to compound
623, compound 625 binds directly to the active site zinc in the
hCA IX-mimic via the sulfamate moiety. In addition, the
ordered water network shows complete displacement. Key
interactions are observed via the five-membered pyrrolidine
linker group with the side chain of His64 (proton-shuttling
residue),29 which further increases the compound’s ability to
abolish CA activity. In addition, a hydrogen bond is formed
between the OH at position 2 of the glucose moiety with Gln92
(Figure 3A). The majority of interactions appear to be with
hydrophobic residues in Val131, Leu91, and Val121 (Figure
3A). In addition, there are vdw interactions forming between
the sulfonyl linker of compound 625 and Leu198. Com-
paratively, compound 625 binds in the active site of hCA II
directly to the active site zinc via the sulfamate moiety and
Figure 3. Compound 625 bound in the active site of both hCA II (green) and the hCA IX-mimic (cyan) with specific residues labeled. (A) Specific
interactions of compound 625 (tan) with the active site of the hCA IX-mimic are shown with relative bond distances shown as black dotted lines
with distances labeled (Å), hydrophobic interactions shown as red dotted lines, and water molecules shown as red spheres. (B) Specific interactions
of compound 625 (pink) with the active site of the hCA II are with relative bond distances shown as black dotted lines with distances labeled (Å),
hydrophobic interactions shown as red dotted lines, and water molecules shown as red spheres. Figure was made using PyMol.38
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induces full displacement of the ordered water network (Figure
3A). There is a clear difference in the orientation of compound
625 in the active site of hCA II compared to the hCA IX-mimic
(Figure 3), which results in a weakening of hydrogen bonding
between Gln92 and His64 as determined by an increase in
relative bond distances (Figure 3B). The acetyl group at
position 6 of the glucose ring in compound 625, as it is bound
in the hCA II active site, shows a direct interaction with the
amide of Asn62 (hydrogen bond distance of 2.9 Å) that most
likely contributes to the compounds stabilization. Compound
625 also shows hydrophobic interactions in hCA II that are
similar to the hCA IX-mimic via interactions with Val121,
Phe131, and Leu198 (Figure 3B). However, there is no
observable interaction with the residue at position 91 (Ile in
hCA II) unlike in the hCA IX-mimic, which also might
contribute to the decrease in the affinity of compound 625 for
hCA II. Most likely, the major contributing factor to the
increased hydrophobic interactions and stronger hydrogen
bonding in the hCA IX active site versus hCA II is the
replacement of Phe131 (hCA II) with Val131 (hCA IX)
(Figure 3). The removal of the aromatic ring in the active site
of hCA IX allows the bulky compound to more readily “fit” in
the enzymes active site via a reduction in steric hindrance. This
is probably the reason compound 625 is even less potent for
hCA I (Ki = 9500 nM, Table 1), which has a phenylalanine in
its active site at position 91 and a tyrosine at position 204 (both
occupy positions in the selective pocket). In addition, the
allowance for compound 625 to readily interact with Leu91 in
the hCA IX-mimic is also predicted to contribute favorable to
its selective inhibition for the enzyme.
A similar phenomenon is observed with compound 625 in
both hCA II and the hCA IX-mimic to that of 623, where there
is clear ester hydrolysis of the acetyl groups of the glucose
moiety (Supporting Information Figure S2B,C). In this
particular case, there is complete ester hydrolysis of all acetyl
groups of the glucose moiety of compound 625 as it resides in
the active site of the hCA IX-mimic causing the compound to
form its deacetylated counterpart, compound 625′ (Figures
S1,S2B). In hCA II, all but the acetyl group at position 6 of the
glucose ring are cleaved. The acetyl group in fact allows for a
key interaction to form with Asn62 in the hCA II active site that
most likely helps the compound to bind to the enzyme (Figure
3B). It is unknown if the arrangement of a specific acetyl group
on the glucose ring plays a role in determining the molecular
propensity for its cleavage and how this translates to the
determined Ki values of the perceived acetylated compound.
Interestingly, this phenomenon occurs after the enzymes (both
hCA II and the hCA IX-mimic) have crystallized and
compounds were soaked into them (see Experimental Section).
The X-ray crystal structure of the hCA IX-mimic in complex
with compound 626 was determined (Table 2). Compound
626 shows selective binding for hCA IX (Ki = 2 nM) that is
∼130-fold that of hCA II (Ki = 265 nM) (Table 1). Previously,
it has been shown that compound 626 binds in the active site of
hCA II and coordinates to the active site zinc via the sulfamate
moiety similar to the other compounds of this series (Figure
4A).30 Also, similar to the previous compounds, there is total
displacement of the ordered water network in the enzyme’s
active site (Figure 4A). These two attributes are also observed
as the compound resides in the active site of the hCA IX-mimic
(Figure 4A,B). Key interactions of compound 626 with hCA II
occur via strong hydrogen bonding (distance = 2.6 Å) between
the O of the sulfonyl linker and the amide on the side chain of
Gln92 and also in coordination with a solvent molecule and the
hydroxyl of the side chain of Asn67 (Figure 4A). In addition,
compound 626 exhibits hydrophobic interactions with the
acetyl group (position 6 of the glucose ring) and Pro202 and
the six-membered piperidine ring and Phe131 (Figure 4A). In
likeness to what has been previously observed, there is ester
hydrolysis of acetyl groups at positions 2, 3, and 4 of the
glucose ring of compound 626 by hCA II.
Key interactions of compound 626 with the active site of the
hCA IX-mimic are observed via hydrogen bonds that are
formed from coordination of the O of the sulfonyl linker, the
amide of the side chain of Gln92, a solvent molecule, and the
amide side chain of Gln67 (Figure 4B). Similarly, there are
hydrogen bonds formed between the carbonyl oxygen of the
acetyl group (position 2 of the glucose ring) and a solvent
molecule that is coordinated between the hydroxyl of the side
chain of Ser65 and the amide side chain of Asn62 (Figure 4A).
Important hydrophobic interactions appear to occur between
the carbons of the glucose ring, Val135 and Pro202 (Figure
Figure 4. Compound 626 bound in the active site of both hCA II (PDB ID 4ZWI, green)30 and the hCA IX-mimic (cyan) with specific residues
labeled. (A) Specific interactions of compound 626 (black) with the active site of hCA II are shown with relative bond distances shown as black
dotted lines with distances labeled (Å), hydrophobic interactions shown as red dotted lines, and water molecules shown as red spheres. (B) Specific
interactions of compound 626 (brown) with the active site of the hCA IX-mimic are shown with relative bond distances shown as black dotted lines
with distances labeled (Å), hydrophobic interactions shown as red dotted lines, and water molecules shown as red spheres. (C) Overlay of
compound 626 with compound 5d (PDB ID 4R5921) to show the change in relative position of the compound from its acetylated to its deacytlated
form with active site residues labeled. Figure was made using PyMol.38
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4B). The selectivity for this compound for hCA IX versus hCA
II most likely occurs via the replacement of Asn for Gln at
position 67 (from hCA II to hCA IX, respectively) which allows
for the formation of additional hydrogen bonding to occur. The
absence of Phe131 (Val in hCA IX) in the active site of hCA IX
most likely allows for a reduction in steric hindrance (similar to
that observed with compound 625), allowing for a more
favorable conformation of compound 626 in the active site of
hCA IX. In addition, this allows for the induction of
hydrophobic interactions with the glucose ring moiety
contributing to the compounds stabilization in the active site.
Ester hydrolyzing events also have been observed to occur
with compound 626 in complex with both hCA II and the hCA
IX-mimic. Interestingly, ester hydrolysis of the acetylglucose
ring occur at different positions between each enzyme such that
hydrolysis of all acetyl groups except for that at position 6 has
been observed in hCA II, and all but the acetyl at position 2
have been hydrolyzed in the hCA IX-mimic (Figure 4A,B).
Currently, the ester hydrolysis of acetyl groups on compound
626 appears random based on our limited data, and there is no
observable trend that indicates which positions of the acetyl
groups on the glucose ring are more likely to undergo ester
hydrolysis. When compound 626 undergoes full ester
hydrolysis to become compound 626′ (Supporting Information
Figure S1), it has previously been shown to display a very high
selectivity ratio for hCA IX over hCA II (>2000-fold).21 There
is, however, a increase in observed Ki value between 626 and
626′ in hCA IX (2 and 10 nM for 626 and 626′, respectively).
This most likely is a result of a loss of interactions between
acetyl groups from compound 626 with the enzymes active site
as previously discussed (Figure 4C). However, it should be
noted this decrease in affinity is slight, and it is more significant
to note that when compound 626 is hydrolyzed to form
compound 626′, there is a substantial reduction in inhibition of
hCA II, which is highly favorable.21 This is reiterated in the
failure of compound 626′ to readily form a complex with hCA
II as noted by Moeker et al.21
Map of the hCA IX Active Site for Isoform Specific
Inhibition. By summarizing observed binding modalities from
each enzyme/inhibitor complex shows that an isoform selective
hCA IX inhibitor must exploit residues in the CA selective pocket
in order to achieve desired specificity. Using the current
structural data within our model system of the hCA IX active
site (via the hCA IX-mimic), in combination with previously
published results, it is possible to map out key attributes of the
hCA IX active site to exploit for isoform specific inhibition of
the enzyme.21,28,31 It has been determined that the least
selective inhibitors utilize mostly hydrophilic interactions in the
hCA active site (Figure 5A). The most important interaction in
the hydrophilic pocket appears to be with Gln67 in the hCA IX
active site, as this forms stabilizing hydrogen bonding networks
that are not present in the hCA II active site. However, it is
clearly evident that the most selective compounds for hCA IX
inhibition form interactions with residues in the enzymes
hydrophobic pocket. We predict the reason for this is the
absence of bulky residues in the hCA IX active site such as
Phe131 (hCA II) and Phe91 and Tyr204 (hCA I) that reduce
the steric hindrance of the compound to (1) more freely enter
the active site and (2) reside in the active site in a favorable
conformation that allows for interactions with residues in the
hydrophobic pocket, such as Leu91, which appears to form
important interactions to induce selectivity (Figure 5B). As
such, Phe131 (hCA II) and Phe91 and Tyr204 (hCA I) can be
referred to as substrate/compound “steric-blocker” residues in
human carbonic anhydrases. Lastly, the relative distance a
compounds “tail” region is located relative to the ZBG has been
shown to be important for selective inhibition. This is also
apparent when comparing previously determined structures of
chemical fragments or compounds that show either high
selectivity for hCA IX or relatively ubiquitous inhibition for all
hCAs. One such case is recent data that suggests sucrose will
selectively bind to hCA IX over hCA II (Kd = 150 mM for hCA
IX and Kd = 450 mM for hCA II).
31 Sucrose binds directly in
the selective pocket of hCA IX which is ∼12 Å from the catalytic
zinc (Figure 5C). Alternatively, compounds that are not
selective form primary interactions that are below or above
the selective pocket (Figure 2B,C). In summary, these
Figure 5. Active-site of the hCA IX-mimic with “mapped” interaction sites for inhibitor selectivity. (A) Compounds 5e (pink, PDB ID 4R5A21) and
626 (brown) overlaid in the hCA IX-mimic active site. Both compounds show a reduced selectivity profile for hCA IX over the other off-target hCAs
compared to other compounds in the sulfamate series. Labeled are active site residue substitutions from hCA II (green) to hCA IX (cyan).
Highlighted are key residues that form important hydrophilic interactions that increase inhibitor selectivity for hCA IX. B). Compounds 5d (orange,
PDB ID 4R5921), 625 (tan), and a saccharin-conjugated hCA IX inhibitor (purple, PDB ID 4RIU28) that exhibited the highest hCA IX selectivity
overlaid in the active site of the hCA IX-mimic (cyan) with substituted residues from hCA II labeled (green). Highlighted are the key interactions
that induce the high hCA IX selective inhibition. (C) Cross-section of the CA active site marking distance shells relative to the active site zinc. The
selective pocket is highlighted in green. Overlays of 4-methylimidazole (light-gray, PDB ID 4HEY41), glycerol (dark-gray, PDB ID 3HS442), and
sucrose (black, PDB ID 4YWP31), which correspond to chemical fragments of none, least, and most selective, respectively. Figure was made using
PyMol.38
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observations provide the necessary parameters that must be
considered when designing hCA IX selective inhibitors.
■ CONCLUSIONS
Previously, it has been determined that the series of
carbohydrate-based sulfamates and their acetylated counter-
parts are excellent inhibitors of hCA IX and hCA XII and highly
selective for these enzymes over the off-target hCA I and II.23
Here, we expand on these findings with novel structural
information that, when coupled with our previous results, have
allowed us to fully map the active site of hCA IX and pinpoint
key interactions that are important for inhibitor selectivity. This
includes taking advantage of key residues of the enzyme’s
selective pocket via designing linker regions of compounds with
specific lengths to allow the compound’s “tail” regions to reach
the residues of the selective pocket located ∼12 Å from the
catalytic zinc. In addition, it is apparent that designing more
bulky compounds induces selective inhibition for hCA IX
because its active site is perceived to be more “open” with the
absence of several aromatic residues, termed hCA substrate/
compound “steric-blocker” residues in the selective pocket of the
enzyme. This essentially allows inhibitors to form highly
favorable hydrophobic interactions that significantly increase
their affinity for hCA IX. In summary, our findings have for the
first time provided a molecular outline of the enzymes active
site that will be advantageous for not only determining useful
SARs of known hCA inhibitors but also provide the framework
to design novel compounds that will be highly potent and
selective for hCA IX, ultimately leading to novel therapies for
the treatment of several cancers.
■ EXPERIMENTAL SECTION
Protein Expression, Purification, and CA IX-Mimic Design.
The hCA IX-mimic construct was engineered by site-directed
mutagenesis of residues in the active site of hCA II to residues
unique to hCA IX, such that the active site of the hCA IX-mimic is
analogous to wild-type hCA IX.32 The advantage of the hCA IX-mimic
is that it is extremely stable and readily crystallizes, allowing direct
structural insight into hCA II versus hCA IX inhibitor binding with a
range of novel small molecules.21,28 Wild-type hCA II and hCA IX-
mimic were expressed and purified using BL21DE3 competent cells as
described by Mahon et al.28 The hCA IX-mimic used for this study
was designed and engineered previously by Genis et al.32 (containing
two active site mutations) and reconstructed by Pinard et al.33 (to
contain seven active site mutations). Utilization of the hCA IX-mimic
was similar to that described by Pinard et al., Mahon et al., and Moeker
et al.21,28,33 Active site mutations in the hCA IX-mimic include: A65S,
N67Q, E69T, I91L, F131V, K170E, and L204A. Purity of each enzyme
was estimated by SDS-PAGE and staining with commassie.
Concentrations were determined by UV/vis spectroscopy and
measured at 22 and 25 mg/mL for the hCA IX-mimic and hCA II,
respectively.
X-ray Crystallography. Purified hCA II and hCA IX-mimic were
crystallized in 1.6 M Na-citrate, 50 mM Tris, pH 7.8, using hanging
drop vapor diffusion.21,28,33 Crystals for both enzymes were observed
after 5 days. Stock solutions of each compound were made using a
100% dimethyl sulfoxide (DMSO) solution and to a final
concentration of ∼50 mM for each. Sock solutions of compounds
were diluted 1:1 (50% DMSO at ∼25 mM) in deionized water prior to
soaking with protein crystals. Crystals were than soaked with the
desired compound solution 24 h prior to data collection. Diffraction
data were collected “in-house” using an RU-H3R rotating Cu anode (λ
= 1.5418 Å) operating at 50 kV and 22 mA utilizing an R-Axis IV+2
image plate detector (Rigaku, USA). Each data set was processed using
HKL2000.34 All data sets were scaled to a P21 space group with
statistics summarized in Table 1. Initial phases for each data set were
determined using molecular replacement methods using PDB 3KS327
as a search model. Molecular replacement, model refinements, and
generation of ligand restraint files were performed using Phenix.35
Models for ligand−protein complexes and PDB files for ligands were
generated using Coot.36,37 Coot36 was also used to determine bond
lengths and angles used for analysis. Figures were generated using
PyMol.38
CA Inhibition Assay. An Applied Photophysics stopped-flow
instrument was used for assaying the CA-catalyzed CO2 hydration
activity.39 IC50 values were obtained from dose−response curves
working at seven different concentrations of test compound; by fitting
the curves using PRISM (www.graphpad.com) and nonlinear least-
squares methods, values represent the mean of at least three different
determinations as described by us previously.40 The inhibition
constants (Ki) were then derived by using the Cheng−Prusoff
equation, as follows: Ki = IC50/(1 + [S]/Km) where [S] represents the
CO2 concentration at which the measurement was carried out and Km
the concentration of substrate at which the enzyme activity is at half-
maximal. All enzymes used were recombinant, produced in Escherichia
coli as reported earlier.40 The concentrations of enzymes used in the
assay were: HCA I, 10.4 nM; HCA II, 8.3 nM; HCA IX, 8.0 nM; and
HCA XII, 12.4 nM.
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